Elucidating The Aberrant TDP-43 Species That Promote Neurodegeneration
阐明促进神经退行性变的异常 TDP-43 物种
基本信息
- 批准号:10385722
- 负责人:
- 金额:$ 34.02万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-06-15 至 2023-03-31
- 项目状态:已结题
- 来源:
- 关键词:ALS patientsAcetylationAlzheimer&aposs DiseaseAutomobile DrivingBehaviorBehavioralBiochemicalCell NucleusCessation of lifeClinicalClustered Regularly Interspaced Short Palindromic RepeatsCognition DisordersCognitive deficitsDataDefectDetectionDiseaseDisease ProgressionDissociationEventFunctional disorderFutureGene Expression ProfileGenetic TranscriptionGoalsHSF1HistologyHumanImpairmentIndividualKnock-in MouseLightLinkLysineMessenger RNAModelingModificationMolecular ChaperonesMotor NeuronsMusMutant Strains MiceMutationNerve DegenerationNeurodegenerative DisordersNeurologicNeuronsNuclearOnset of illnessPathogenesisPathogenicityPathologicPathologyPhysiologicalRNA Recognition MotifRoleSignal TransductionSymptomsSyndromeTestingTherapeuticToxic effectapproach behaviorbaseeffective therapyfrontotemporal lobar dementia-amyotrophic lateral sclerosisgain of functionhuman diseasein vivoin vivo evaluationinnovationinsightmotor deficitmotor disordermouse modelneurodegenerative phenotypeneuron losspreventprotein TDP-43proteostasisresponsetherapeutic targettranscription factortranscriptometranscriptome sequencingtreatment strategy
项目摘要
TDP-43 dysfunction underlies a spectrum of neurodegenerative diseases collectively known as TDP-43
proteinopathies, which are characterized by neuronal loss, behavioral abnormalities, and ultimately death.
Surprisingly, little is known about how TDP-43 undergoes such a dramatic transformation that initiates disease
progression. Recently, we discovered that TDP-43 is subject to reversible lysine acetylation, a modification
within TDP-43’s RNA-binding domain that has a remarkable effect; it disengages TDP-43 from its target
mRNAs and accelerates TDP-43’s propensity to aggregate. Indeed, acetylated TDP-43 inclusions were
detected in motor neurons of amyotrophic lateral sclerosis (ALS) patients, suggesting a role for this aberrantly
modified form of TDP-43 in disease pathogenesis. We leveraged this intriguing finding to generate the first
CRISPR-based, non-transgenic TDP-43 mouse model containing an acetylation-mimicking mutation, thus
producing a physiologically relevant model of TDP-43 proteinopathy. We hypothesize that TDP-43
acetylation drives neurodegeneration and disease progression, which can now be directly tested in
vivo. Our preliminary data already show evidence of TDP-43 pathology, nuclear TDP-43 clearing, and
prominent behavioral defects in mutant mice. In Aim-1, we will use histology, biochemical, and behavior
approaches to fully characterize the neurodegenerative phenotype. In Aim-2, we shed light on the therapeutic
potential of activating the master transcription factor HSF1, or specific downstream chaperones, to induce a
highly coordinated transcriptional cascade capable of suppressing acetylated TDP-43 dysfunction and
restoring nuclear TDP-43 levels. Finally, in Aim-3, we will uncover early-stage perturbations in the
transcriptome that occur in response to acetylated TDP-43, but emerge prior to overt neurodegeneration and
behavioral defects. Our proposal is significant since it will highlight an aberrant form of TDP-43 as a plausible
therapeutic target, it will pinpoint specific chaperone responses as new avenues to detoxify neurons, and it will
illuminate transcriptional dysregulation as a critical pathomechanism associated with neurodegeneration. Our
proposal is also innovative since we will shed light on aberrant TDP-43 modifications as plausible triggers for
disease onset or progression.
TDP-43功能障碍是一系列神经退行性疾病的基础,统称为TDP-43
蛋白质病,以神经元丢失、行为异常和最终死亡为特征。
令人惊讶的是,人们对TDP-43如何经历如此戏剧性的转变而引发疾病知之甚少。
进步。最近,我们发现TDP-43受到可逆的赖氨酸乙酰化的影响,这是一种修饰
在TDP-43‘S的RNA结合区内,有显著的作用;它使TDP-43与其靶标解离
并加速TDP-43‘S的聚集倾向。事实上,乙酰化的TDP-43包裹体是
在肌萎缩侧索硬化症(ALS)患者的运动神经元中检测到,这表明这一异常的作用
TDP-43修饰形式在疾病发病机制中的作用我们利用这一有趣的发现产生了第一个
基于CRISPR的非转基因TDP-43小鼠模型含有类似乙酰化的突变,因此
制作与生理相关的TDP-43蛋白病变模型。我们假设TDP-43
乙酰化会导致神经退化和疾病进展,现在可以直接在
活着。我们的初步数据已经显示出TDP-43病理、核TDP-43清除以及
突变小鼠的显著行为缺陷。在AIM-1中,我们将使用组织学、生化和行为学
全面描述神经退行性变表型的方法。在AIM-2中,我们阐明了治疗
激活主转录因子HSF1或特定下游伴侣蛋白的潜力,以诱导
高度协调的转录级联能够抑制乙酰化的TDP-43功能障碍和
恢复核TDP-43水平。最后,在AIM-3中,我们将揭示早期阶段的扰动
发生于乙酰化的TDP-43的转录组,但出现在明显的神经变性和
行为缺陷。我们的建议意义重大,因为它将突出TDP-43的异常形式是一种看似合理的
治疗目标,它将确定特定的伴侣反应作为新的途径来为神经元解毒,它将
阐明转录失调是与神经退行性变相关的关键病理机制。我们的
该提案也是创新的,因为我们将阐明异常的TDP-43修改是
疾病的发生或发展。
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Tandem detergent-extraction and immunoprecipitation of proteinopathy: Scalable enrichment of ALS-associated TDP-43 aggregates.
- DOI:10.1016/j.isci.2023.106645
- 发表时间:2023-05-19
- 期刊:
- 影响因子:5.8
- 作者:Evangelista, Baggio A.;Cahalan, Shannon R.;Ragusa, Joey V.;Mordant, Angie;Necarsulmer, Julie C.;Perna, Robert J.;Ajit, Tejazaditya;White, Kristen;Barker, Natalie K.;Tian, Xu;Cohen, Sarah;Meeker, Rick;Herring, Laura E.;Cohen, Todd J.
- 通讯作者:Cohen, Todd J.
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Todd Jonathan Cohen其他文献
Todd Jonathan Cohen的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Todd Jonathan Cohen', 18)}}的其他基金
Identifying kinase signaling pathways linked to tau-mediated neurodegeneration
识别与 tau 介导的神经变性相关的激酶信号通路
- 批准号:
10753257 - 财政年份:2023
- 资助金额:
$ 34.02万 - 项目类别:
CRISPR gene therapies targeting tau in Alzheimer's disease and tauopathies
针对阿尔茨海默病和 tau 病中 tau 蛋白的 CRISPR 基因疗法
- 批准号:
10752745 - 财政年份:2023
- 资助金额:
$ 34.02万 - 项目类别:
Sleep-dependent synaptic homeostasis in Alzheimer's disease
阿尔茨海默病中睡眠依赖性突触稳态
- 批准号:
10209327 - 财政年份:2021
- 资助金额:
$ 34.02万 - 项目类别:
Identifying Alzheimer’s Disease Causal Variants and Target Genes Using iPSC-derived Microglia
使用 iPSC 衍生的小胶质细胞识别阿尔茨海默病致病变异和靶基因
- 批准号:
10382389 - 财政年份:2020
- 资助金额:
$ 34.02万 - 项目类别:
Identifying Alzheimer’s Disease Causal Variants and Target Genes Using iPSC-derived Microglia
使用 iPSC 衍生的小胶质细胞识别阿尔茨海默病致病变异和靶基因
- 批准号:
10615602 - 财政年份:2020
- 资助金额:
$ 34.02万 - 项目类别:
Dual CHIP Functions Control Tau Triage In Alzheimer's Disease
双芯片功能控制阿尔茨海默氏病的 Tau 分类
- 批准号:
10088361 - 财政年份:2019
- 资助金额:
$ 34.02万 - 项目类别:
Dual CHIP Functions Control Tau Triage In Alzheimer's Disease
双芯片功能控制阿尔茨海默氏病的 Tau 分类
- 批准号:
10319914 - 财政年份:2019
- 资助金额:
$ 34.02万 - 项目类别:
Dual CHIP Functions Control Tau Triage In Alzheimer's Disease
双芯片功能控制阿尔茨海默氏病的 Tau 分类
- 批准号:
10539271 - 财政年份:2019
- 资助金额:
$ 34.02万 - 项目类别:
TDP-43 acetylation as a pathogenic modification in ALS & related proteinopathies
TDP-43 乙酰化作为 ALS 的致病修饰
- 批准号:
8849550 - 财政年份:2014
- 资助金额:
$ 34.02万 - 项目类别:
TDP-43 acetylation as a pathogenic modification in ALS & related proteinopathies
TDP-43 乙酰化作为 ALS 的致病修饰
- 批准号:
8862550 - 财政年份:2014
- 资助金额:
$ 34.02万 - 项目类别:
相似海外基金
Investigating the functions of histone acetylation in genome organization and leukemogenesis
研究组蛋白乙酰化在基因组组织和白血病发生中的功能
- 批准号:
EP/Y000331/1 - 财政年份:2023
- 资助金额:
$ 34.02万 - 项目类别:
Research Grant
Gene Modulation of Acetylation Modifiers to Reveal Regulatory Links to Human Cardiac Electromechanics
乙酰化修饰剂的基因调节揭示与人类心脏机电的调节联系
- 批准号:
10677295 - 财政年份:2023
- 资助金额:
$ 34.02万 - 项目类别:
Novel roles of PDK2 in heart failure: Regulation of mitochondrial nuclear crosstalk via metabolic regulation and histone acetylation
PDK2 在心力衰竭中的新作用:通过代谢调节和组蛋白乙酰化调节线粒体核串扰
- 批准号:
10635599 - 财政年份:2023
- 资助金额:
$ 34.02万 - 项目类别:
Regulation of hepatic lysine N-acetylation by cysteine proximity due to alcohol toxicity
酒精毒性导致的半胱氨酸接近对肝脏赖氨酸 N-乙酰化的调节
- 批准号:
10752320 - 财政年份:2023
- 资助金额:
$ 34.02万 - 项目类别:
Histone Acetylation Regulates Microglial Innate Immune Memory
组蛋白乙酰化调节小胶质细胞先天免疫记忆
- 批准号:
478927 - 财政年份:2023
- 资助金额:
$ 34.02万 - 项目类别:
Operating Grants
Dysregulation of Histone Acetylation in Parkinson's Disease
帕金森病中组蛋白乙酰化的失调
- 批准号:
10855703 - 财政年份:2023
- 资助金额:
$ 34.02万 - 项目类别:
Obesity-related hypertension: the contribution of PPAR gamma acetylation and asprosin
肥胖相关高血压:PPAR γ 乙酰化和白脂素的贡献
- 批准号:
10654210 - 财政年份:2023
- 资助金额:
$ 34.02万 - 项目类别:
The role N-terminal acetylation in dilated cardiomyopathy and associated arrhythmia
N-末端乙酰化在扩张型心肌病和相关心律失常中的作用
- 批准号:
10733915 - 财政年份:2023
- 资助金额:
$ 34.02万 - 项目类别:
In vivo tracing of hepatic ethanol metabolism to histone acetylation: role of ACSS2 in alcohol-induced liver injury
肝脏乙醇代谢与组蛋白乙酰化的体内追踪:ACSS2 在酒精性肝损伤中的作用
- 批准号:
10667952 - 财政年份:2023
- 资助金额:
$ 34.02万 - 项目类别:
The function of TWIST1 acetylation in cell fate and tissue development
TWIST1 乙酰化在细胞命运和组织发育中的作用
- 批准号:
10726986 - 财政年份:2023
- 资助金额:
$ 34.02万 - 项目类别:














{{item.name}}会员




